Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Virginia
19 open options
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALNAENROLLING_BY_INVITATION
Mild Cognitive Impairment and Neuromodulation
Low intensity focused ultrasound · Sham (No Treatment) — 1 site
- TRIALPHASE4RECRUITING
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
Syn-One skin biopsy · Multi modal MRI · Assessment of dynamic EEG features over 48-hour periods across all study aims — 1 site
- TRIALNARECRUITING
Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers
Structured Retrieval Practice · Reading-Based Education — 1 site
- TRIALPHASE2RECRUITING
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
SHUTi OASIS · Patient Education — 1 site
- TRIALNARECRUITING
mHealth Intervention for Pain Self Management
Mobile Health (mHealth) Intervention — 1 site
- TRIALNARECRUITING
The Role of the Locus Coeruleus in Age-related Distractibility
Tablet based adaptive multimodal attention practice program · Tablet based adaptive criterion task practice program — 1 site
- TRIALPHASE2RECRUITING
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
LHP588 · LHP588 · Placebo Drug — 40 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNAENROLLING_BY_INVITATION
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Sensory Stimulation System (GS120) - Active — 53 sites
- TRIALPHASE2RECRUITING
Open-label Extension Study in Participants With Early Alzheimer's Disease
GSK4527226 — 33 sites
- TRIALPHASE2RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Donanemab · Placebo — 72 sites
- TRIALPHASE2RECRUITING
Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
THC-free CBD Oil · Placebo — 1 site
- TRIALPHASE3RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 143 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
KarXT · Placebo — 292 sites
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 150 sites
- TRIALPHASE1 / PHASE2RECRUITING
Rifaximin SSD in Dementia Trial
Rifaximin SSD 40 mg IR tablet · Placebo — 1 site
- TRIALPHASE2RECRUITING
Clinical Trial on Agitation in Alzheimer's Dementia
IGC-AD1-Active · IGC-AD1-Placebo — 31 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.